Filing Flows › Tenaya Therapeutics (TNYA) › Q3 2026
Tenaya Therapeutics (TNYA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Tenaya Therapeutics (TNYA) reported revenue of $1.7M for the third quarter 2026 (Q3 2026) and +53% from the quarter before.
Tenaya Therapeutics, Q3 2026: revenue $1.7M, net loss $18.9M, operating cash flow −$17.7M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.7M | +53% | — |
| Operating profit | −$19.6M | — | — |
| Net earnings | −$18.9M | — | — |
| Operating cash flow | −$17.7M | — | — |
What changed
Revenue was $1.7M in Q3 2026, up 53% from the previous quarter.
Operating costs exceeded revenue by $19.6M, an operating margin of -1153.3%. The quarter ended with a net loss of $18.9M, narrower than the previous quarter's $43.4M loss.
Operating cash flow was −$17.7M. Non-cash charges added back $394K of depreciation and amortization and $1.7M of share-based compensation.
Questions
What was Tenaya Therapeutics' revenue in the third quarter 2026?
Tenaya Therapeutics (TNYA) reported revenue of $1.7M for the third quarter 2026 (Q3 2026) and +53% from the quarter before.